SAFYRAL

Peak

drospirenone/ethinyl estradiol/levomefolate calcium and levomefolate calcium

NDAORALTABLET

Approved

Dec 2010

Lifecycle

Peak

Competitive Pressure

8/100

Mechanism of Action

ovulation.

Indications (3)

females of reproductive potential to raise folate levels for the purpose of reducing the risk of a neural tube defect in a pregnancy conceived while taking the product shortly after discontinuing the product

Loss of Exclusivity

LOE Date

Jul 17, 2030

53 months away

Patent Expiry

Jul 17, 2030

Patent Records (2)

Patent #	Expiry	Type	Use Code
8617597	Feb 8, 2030	Product	—
11617751	Jul 17, 2030	Product	U-3572

Company

LEVERKUSEN, Germany

External Resources

Full prescribing information

FDA approval history

Drug nomenclature & identifiers